<DOC>
	<DOC>NCT01756781</DOC>
	<brief_summary>This is a drug-drug interaction study to compare the pharmacokinetics of a 2 mg oral dose of midazolam in adult healthy women of non-childbearing potential when administered alone and when administered along with 8 daily 125 mg doses of PD-0332991. Volunteers will be randomized to one of two sequences. Volunteers in sequence 1 will receive midazolam alone in treatment period 1, followed by multiple dose PD-0332991 and midazolam in treatment period 2. Volunteers randomized to sequence 2 will receive multiple dose PD-0332991 and midazolam in treatment period 1, and following a washout period of no less than 14 days they will receive midazolam alone in treatment period 2.</brief_summary>
	<brief_title>A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.</brief_title>
	<detailed_description />
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Healthy females of nonchild bearing potential between the ages of 18 and 65 years old. A Body Mass Index (BMI) of 17.5 to 32.0 kg/m2 and a total body weight &gt;50 kg (110 lbs). A signed informed consent document. Any evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. A positive urine drug screen. Pregnant or nursing females. Treatment with an investigational drug within 30 days or 5 halflives of the first dose of study medication.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>PD-0332991</keyword>
	<keyword>Midazolam</keyword>
	<keyword>Drug-Drug Interaction Study</keyword>
	<keyword>Healthy Adult Volunteer</keyword>
</DOC>